Jul 25, 2023 · CCR4-CAR T cells were characterized by high transduction efficiency, robust T-cell expansion, and rapid fratricidal depletion of CCR4-positive T cells during CAR transduction …

Jul 12, 2023 · CCR4 CAR is active against T-cell lymphoma. Fratricide induced by CCR4 CAR selectively depletes Th2, Th17, and Treg while sparing Th1.

Grover et al are conducting a phase I/II clinical trial, in which patients with r/r cHL and CD30+ T cell lymphoma of the skin are being treated with autologous CD30 CAR-T cells expressing the …

Feb 25, 2025 · Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy, in which engineered T cells express a synthetic CAR that targets tumor antigens in a major histocompatibility …

This experiment’s characteristics included high transduction efficiency, robust T-cell proliferation, and fast fratricidal elimination of CCR4-positive T-cells during CAR transduction and expansion.

Taking a different approach, we have developed a lentiviral gene transfer system to genetically engineer autologous T cells to express a chimeric antigen receptor (CAR) that targets CCR4 …

Nov 5, 2021 · Our data confirm the safety of CCR4.CD30.CAR-Ts as well as their promising efficacy in patients with r/r HL. Interestingly, responses are already seen at the lowest dose …

The present disclosure provides anti-CCR4 chimeric antigen receptors (CARs) and compositions and methods for modified immune cells or precursors thereof (e.g., modified T cells) comprising...

Mogamulizumab is a fully humanized and glyco-engineered monoclonal anti-CCR4 antibody used for the treatment of refractory/relapsed ATLL and CTCLs, often resulting in complete …

Jun 18, 2009 · Improved migration of activated T lymphocytes genetically modified to overexpress CCR4 and a CAR targeting the CD30 antigen expressed by HL. A bicistronic vector encoding …